Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 2/20 | 0.44 |
| ▸ | FLT3 | P36888 | 4/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4293328 | 0.94 | FLT3 (0.48) | CHEK2FLT3HSD17B10GAADRD2 | |
| SCHEMBL4287769 | 0.85 | GAA (0.57) | HSD17B10GAADRD2SLC6A4FGFR1 | |
| SCHEMBL3352200 | 0.82 | GAA (0.61) | FLT3HSD17B10GAADRD2SLC6A4 | |
| SCHEMBL15944159 | 0.79 | DRD2 (0.45) | FLT3DRD2SLC6A4FGFR1PRMT5 | |
| SCHEMBL3729078 | 0.79 | DRD2 (0.64) | DRD2SLC6A4PRMT5USP2ALDH1A1 | |
| SCHEMBL15943820 | 0.77 | DRD2 (0.43) | FLT3GAADRD2SLC6A4PRMT5 | |
| SCHEMBL3352559 | 0.77 | ALDH1A1 (0.53) | FLT3HSD17B10GAADRD2SLC6A4 | |
| SCHEMBL31030883 | 0.76 | IDO1 (0.45) | HSD17B10GAAFGFR1ALDH1A1HPGD | |
| SCHEMBL14852148 | 0.76 | FLT3 (0.45) | FLT3HSD17B10GAADRD2SLC6A4 | |
| SCHEMBL22862454 | 0.75 | GAA (0.53) | FLT3HSD17B10GAAFGFR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303182-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | NOVARTIS AG (CH) | 2014-10-09 | — | — | US | disclosed |
| US-20130338171-A1 | Pharmaceutically Acceptable Salts of Quinolinone Compounds Having Improved Pharmaceutical Properties | NOVARTIS AG (CH) | 2013-12-19 | — | — | US | disclosed |
| US-20130018058-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | CAI SHAOPEI (US) | 2013-01-17 | — | — | US | disclosed |
| US-20090181979-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-20050209247-A1 | Lactate salt of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; improved water solubility and physicochemical properties (e.g., stability, hygroscopicity, crystallinity, and compactibility); vascular endothelial growth factor receptor tyrosine kinase inhibitors | CHIRON CORPORATION | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338171-A1 | Pharmaceutically Acceptable Salts of Quinolinone Compounds Having Improved Pharmaceutical Properties | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB14, SLC13A3 | CHEK2 3126/4885FLT3 2692/4885HSD17B10 1495/4885 |
| US-20090181979-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB14, SLC13A3 | CHEK2 3126/4885FLT3 2692/4885HSD17B10 1495/4885 |
| US-20050209247-A1 | Lactate salt of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; improved water solubility and physicochemical properties (e.g., stability, hygroscopicity, crystallinity, and compactibility); vascular endothelial growth factor receptor tyrosine kinase inhibitors | KDR, FLT4, FLT1 | CHEK2 873/4885FLT3 48/4885HSD17B10 2437/4885 |
| US-20140303182-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB14, SLC13A3 | CHEK2 3126/4885FLT3 2692/4885HSD17B10 1495/4885 |
| US-20130018058-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB14, SLC13A3 | CHEK2 3126/4885FLT3 2692/4885HSD17B10 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.